IGFBPL1 TCE / Myrio Therap - LARVOL DELTA

Development of a T cell engager against IGFBPL1: A novel target for small cell lung cancer and other neuroendocrine cancers (AACR 2026) - "FDA approval of tarlatamab, a T cell engager targeting DLL3, has delivered a new treatment option for patients with relapsed disease and spurred enthusiasm for T cell engagers and other DLL3-targeted therapies for SCLC. Our data support development of a novel T cell engager for SCLC based on IGFBPL1 targeting. This potential therapy provides another option to DLL3-targeting therapies in the clinic and under investigation, to overcome this challenging and devastating disease."

Endocrine Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • HLA-A • IGFBP1